United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 150 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - hepatitis b virus subtype adw2 hbsag surface protein antigen (unii: 9gcj1l5d1p) (hepatitis b virus subtype adw2 hbsag surface protein antigen - unii:9gcj1l5d1p) - hepatitis b virus subtype adw2 hbsag surface protein antigen 20 ug in 1 ml - engerix-b is indicated for immunization against infection caused by all known subtypes of hepatitis b virus. as hepatitis d (caused by the delta virus) does not occur in the absence of hepatitis b infection, it can be expected that hepatitis d will also be prevented by engerix-b vaccination. engerix-b will not prevent hepatitis caused by other agents, such as hepatitis a, c, and e viruses, or other pathogens known to infect the liver. immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis b virus,1 for example: - infants, including those born of hbsag-positive mothers (see dosage and administration.) - adolescents (see clinical pharmacology.) - healthcare personnel: dentists and oral surgeons. dental, medical, and nursing students. physicians, surgeons, and podiatrists. nurses. paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. dental hygienists and dental n

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - pioglitazone hydrochloride 15 mg - actos is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see clinical studies (14)] . actos exerts its antihyperglycemic effect only in the presence of endogenous insulin. actos should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.3)] . do not initiate in patients with nyha class iii or iv heart failure [see boxed warning] . do not use in patients with a history of a serious hypersensitivity reaction to actos or any of its ingredients. pregnancy category c. there are no adequate and well-controlled studies of actos in pregnant women. animal studies show increased rates of post-implantation loss, delayed development, reduced fetal weights, and delayed parturition at doses 10 to 40 times the maximum recommended human dose. actos should be used during pregnancy only if the p

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s) - pioglitazone 15 mg - pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see clinical studies (14)] . pioglitazone tablet exerts its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.3)]. do not initiate in patients with nyha class iii or iv heart failure [see boxed warning] . do not use in patients with a history of a serious hypersensitivity reaction to pioglitazone tablets or any of its ingredients. pregnancy category c. there are no adequate and well-controlled studies of pioglitazone hydrochloride in pregnant women. animal studies show increased rates of post-implantation loss, delayed development, reduced fetal weights, and delayed parturition at doses 10 to 40 times the maxim

United States - English - NLM (National Library of Medicine)

homeopathystore.com - horse chestnut (unii: 3c18l6rjaz) (horse chestnut - unii:3c18l6rjaz), antimony trisulfide (unii: f79059a38u) (antimony cation (3+) - unii:069647rpt5), silver nitrate (unii: 95it3w8jze) (silver cation - unii:57n7b0k90a, nitrate ion - unii:t93e9y2844), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10), ceanothus a - horse chestnut 6 [hp_x] in 50 ml - helps rid body of toxins and waste due to unbalanced diet, exposure to environmental pollutants, use of medications including antibiotics, smoking, excessive caffeine and alcohol consumption. cleanses liver, lungs, skin, kidneys, intestines.

United States - English - NLM (National Library of Medicine)

padagis us llc - activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10) - activated charcoal 25 g in 25 g - poison adsorbent for emergency use to adsorb swallowed poisons

United States - English - NLM (National Library of Medicine)

natural creations, inc. - activated charcoal (unii: 2p3vwu3h10) (activated charcoal - unii:2p3vwu3h10), copper (unii: 789u1901c5) (copper - unii:789u1901c5), drosera rotundifolia (unii: qr44n9xpjq) (drosera rotundifolia - unii:qr44n9xpjq), ipecac (unii: 62i3c8233l) (ipecac - unii:62i3c8233l), lachesis muta venom (unii: vsw71ss07i) (lachesis muta venom - unii:vsw71ss07i), lobelia inflata (unii: 9pp1t3tc5u) (lobelia inflata - unii:9pp1t3tc5u), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w), pulsatilla vulgaris (un - activated charcoal 30 [hp_x] in 1 ml - uses: temporarily relieves dry, spasmodic, irritating cough with hoarseness.** uses: temporarily relieves dry, spasmodic, irritating cough with hoarseness.**

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 300 mg - nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi pasteur msd ltd - human poliovirus type 1 inactivated; human poliovirus type 3 inactivated; human poliovirus type 2 inactivated - suspension for injection